-transparent.png){kind=logo}
The effect of Prednimustine was evaluated in 37 patients with generalised non-Hodgkin's lymphomas. The patients were divided into three groups according to dosage and previous treatment. Totally, in all three groups, 22 complete and 10 partial remissions were observed. During follow-up, five of the complete responders and all partial responders have relapsed. Leucopenia and thrombocytopenia were induced in several patients, but were always moderate and reversible after withdrawal of the drug. In some patients with a history of peptic ulcer or diabetes mellitus, these conditions were aggravated.
Related Publications
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1993,
Medical oncology and tumor pharmacotherapy,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1977,
Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1978,
Cancer,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1989,
Therapie,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
November 1979,
Scandinavian journal of haematology,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1977,
European journal of cancer,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
March 1979,
Cancer treatment reports,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
June 2001,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
January 1980,
European journal of cancer,
L Håkansson, and
I Könyves, and
L G Lindberg, and
T Möller
October 1998,
American journal of hematology,
